Lord Abbett
Lord Abbett & Co. LLC is an independent, employee-owned investment management firm based in Jersey City, New Jersey, founded in 1929. The firm offers a wide range of investment services primarily to individuals, including high net worth clients, as well as institutional clients such as pension plans, corporations, and charitable organizations. Lord Abbett manages client-focused portfolios across equity, fixed income, and balanced strategies, while also launching various mutual funds. The firm invests in public equity and fixed income markets globally, with a particular emphasis on the United States and emerging markets. Its investment approach encompasses a mix of quantitative and fundamental analysis, focusing on growth, value, and dividend-paying stocks across various market capitalizations. In fixed income, Lord Abbett invests in a range of securities including municipal bonds, corporate securities, and government securities, employing a comprehensive strategy to enhance performance.
Coherus Biosciences
Post in 2020
Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.